Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Tesetaxel

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Tesetaxel
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC46H60FN3O13
Molar mass881.992 g·mol−1
3D model (JSmol)
  • CC1=C2[C@@H]3[C@H]([C@@]4(CC[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)O[C@@H](O3)CN(C)C
  • InChI=1S/C46H60FN3O13/c1-24-28(58-40(54)34(52)33(32-27(47)17-14-20-48-32)49-41(55)63-42(3,4)5)21-46(56)38(61-39(53)26-15-12-11-13-16-26)36-44(8,19-18-29-45(36,23-57-29)62-25(2)51)37-35(31(24)43(46,6)7)59-30(60-37)22-50(9)10/h11-17,20,28-30,33-38,52,56H,18-19,21-23H2,1-10H3,(H,49,55)/t28-,29+,30+,33-,34+,35+,36-,37+,38-,44+,45-,46+/m0/s1 ☒N
  • Key:MODVSQKJJIBWPZ-VLLPJHQWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tesetaxel is an orally administeredtaxane being investigated as achemotherapy agent for various types of cancer, includingbreast cancer,[1]gastric cancer,[2]colorectal cancer,[3] and other solid tumors.[4] It differs from other members of the taxane class (e.g.paclitaxel ordocetaxel) in that it is administered orally, not intravenously.[5]

References

[edit]
  1. ^Clinical trial numberNCT01221870 for "Tesetaxel as First-line Therapy for Metastatic Breast Cancer" atClinicalTrials.gov
  2. ^Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R, Anthoney DA (June 2006). "A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen".Journal of Clinical Oncology.24 (18_suppl): 4081.doi:10.1200/jco.2006.24.18_suppl.4081.
  3. ^Clinical trial numberNCT00080834 for "DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma" atClinicalTrials.gov
  4. ^Clinical trial numberNCT01315431 for "A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors" atClinicalTrials.gov
  5. ^Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (May 2003)."DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo".Cancer Science.94 (5):459–66.doi:10.1111/j.1349-7006.2003.tb01465.x.PMC 11160250.PMID 12824894.
SPs/MIs
(M phase)
Blockmicrotubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tesetaxel&oldid=1228264943"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp